Chris Mason

发表

BTRFS: The Linux B-Tree Filesystem

Josef Bacik, Ohad Rodeh, Chris Mason, 2013, TOS.

Stem cells: the blue print for the future.

Chris Mason, 2006, Medical device technology.

The Translation Cycle: round and round in cycles is the only way forward for regenerative medicine.

Chris Mason, Elisa Manzotti, C. Mason, 2010, Regenerative medicine.

Regen: the industry responsible for cell-based therapies.

Chris Mason, Elisa Manzotti, C. Mason, 2009, Regenerative medicine.

Transcendent Memory and Linux

Chris Mason, Oracle Corp, Dan Magenheimer, 2006 .

Regenerative medicine bioprocessing: building a conceptual framework based on early studies.

Chris Mason, Mike Hoare, C. Mason, 2006, Tissue engineering.

Reproducible culture and differentiation of mouse embryonic stem cells using an automated microwell platform☆

Waqar Hussain, Farlan S. Veraitch, Gary J. Lye, 2013, Biochemical engineering journal.

Paravirtualized Paging

Chris Mason, Daniel J. Magenheimer, Dave McCracken, 2008, Workshop on I/O Virtualization.

International community consensus standard for reporting derivation of human embryonic stem cell lines.

Chris Mason, Emma L Stephenson, Peter R Braude, 2007, Regenerative medicine.

Systems Engineering and Tram Projects

Chris Mason, 2008 .

High performance , high accuracy FDTD implementation on GPU architectures

Michal Okoniewski, Nicolas Chavannes, Chris Mason, 2010 .

Automated tissue engineering: a major paradigm shift in health care.

Chris Mason, 2003, Medical device technology.

Polygon Generalization with Circle Arcs

Peter A. Whigham, Chris Mason, Antoni Moore, 2012, GSR.

What Is the Greatest Regulatory Challenge in the Translation of Biomaterials to the Clinic?

Chris Mason, Glenn D Prestwich, Christopher K Breuer, 2012, Science Translational Medicine.

The strong financial case for regenerative medicine and the regen industry.

Chris Mason, Peter Dunnill, C. Mason, 2008, Regenerative medicine.

A decade of cell therapy clinical trials (2000-2010).

Simon Edwards-Parton, Chris Mason, David A Brindley, 2012, Regenerative medicine.

A new cell therapy sector arising from the convergence of cell and gene therapy

Simon Edwards-Parton, W. Folkerts, Chris Mason, 2013 .

Regenerative medicine 2.0.

Chris Mason, C. Mason, 2007, Regenerative medicine.

Cell Therapy Regulatory Toolkit: an online regulatory resource.

Chris Mason, Julian Hitchcock, James Lawford Davies, 2015, Regenerative medicine.

The time has come to engineer tissues and not just tissue engineer.

Chris Mason, 2006, Regenerative medicine.

The impact of manual processing on the expansion and directed differentiation of embryonic stem cells

Chris Mason, Farlan S Veraitch, Gary J Lye, 2008, Biotechnology and bioengineering.

Commission : Stem cells and regenerative medicine

Giulio Cossu, Francesco Muntoni, Chris Mason, 2017 .

Pharmaceutical industry: Investors unfazed by drug-patent expiry

David Brindley, Chris Mason, Brock Reeve, 2012, Nature.

Translational regenerative medicine research: essential to discovery and outcome.

Chris Mason, Peter Dunnill, 2007, Regenerative medicine.

A novel filtration device for point of care preparation of cellular therapies

Farlan S. Veraitch, Chris Mason, Rui Tostoes, 2015 .

Regenerative medicine bioprocessing: the need to learn from the experience of other fields.

Mike Hoare, Chris Mason, C. Mason, 2006, Regenerative medicine.

Streamlining Cell Therapy Manufacture

Chris Mason, C. Mason, D. Brindley, 2012 .

Peak serum: implications of serum supply for cell therapy manufacturing.

Chris Mason, Jon A Rowley, David A Brindley, 2012, Regenerative medicine.

Regenerative medicine cell therapies: numbers of units manufactured and patients treated between 1988 and 2010.

Chris Mason, Elisa Manzotti, C. Mason, 2010, Regenerative medicine.

Mechanical dynamics of single cells during early apoptosis.

Chris Mason, Farlan S Veraitch, M. Horton, 2009, Cell motility and the cytoskeleton.